These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 24446810)

  • 1. Delivery of polysaccharides using polymer particles: implications on size-dependent immunogenicity, opsonophagocytosis, and protective immunity.
    Anish C; Khan N; Upadhyay AK; Sehgal D; Panda AK
    Mol Pharm; 2014 Mar; 11(3):922-37. PubMed ID: 24446810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunogenic characteristics associated with multivalent display of Vi polysaccharide antigen using biodegradable polymer particles.
    Anish C; Goswami DG; Kanchan V; Mathew S; Panda AK
    Biomaterials; 2012 Oct; 33(28):6843-57. PubMed ID: 22748669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral immune response of a pneumococcal conjugate vaccine: capsular polysaccharide serotype 14-Lysine modified PspA.
    Santamaria R; Goulart C; Perciani CT; Barazzone GC; Carvalho R; Gonçalves VM; Leite LC; Tanizaki MM
    Vaccine; 2011 Nov; 29(47):8689-95. PubMed ID: 21906649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct approaches to investigate the importance of the murine 4-1BB 4-1BBL interaction in the antibody response to Streptococcus pneumoniae.
    Moens L; Jeurissen A; Mittler RS; Wuyts G; Michiels G; Boon L; Ceuppens JL; Bossuyt X
    J Leukoc Biol; 2007 Sep; 82(3):638-44. PubMed ID: 17550973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide mimics of two pneumococcal capsular polysaccharide serotypes (6B and 9V) protect mice from a lethal challenge with Streptococcus pneumoniae.
    Smith CM; Lo Passo C; Scuderi A; Kolberg J; Baxendale H; Goldblatt D; Oggioni MR; Felici F; Andrew PW
    Eur J Immunol; 2009 Jun; 39(6):1527-35. PubMed ID: 19499518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.
    Nguyen CT; Kim SY; Kim MS; Lee SE; Rhee JH
    Vaccine; 2011 Aug; 29(34):5731-9. PubMed ID: 21696869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiplex opsonophagocytosis assay (MOPA): a useful tool for the monitoring of the 7-valent pneumococcal conjugate vaccine.
    Bogaert D; Sluijter M; De Groot R; Hermans PW
    Vaccine; 2004 Sep; 22(29-30):4014-20. PubMed ID: 15364451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae.
    Xu J; Dai W; Wang Z; Chen B; Li Z; Fan X
    Clin Vaccine Immunol; 2011 Jan; 18(1):75-81. PubMed ID: 21047997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP.
    Cao J; Chen D; Xu W; Chen T; Xu S; Luo J; Zhao Q; Liu B; Wang D; Zhang X; Shan Y; Yin Y
    Vaccine; 2007 Jun; 25(27):4996-5005. PubMed ID: 17524530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early life T cell responses to pneumococcal conjugates increase with age and determine the polysaccharide-specific antibody response and protective efficacy.
    Jakobsen H; Hannesdottir S; Bjarnarson SP; Schulz D; Trannoy E; Siegrist CA; Jonsdottir I
    Eur J Immunol; 2006 Feb; 36(2):287-95. PubMed ID: 16385627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of pneumococcal disease through vaccination.
    Gentile A; Bazán V
    Vaccine; 2011 Sep; 29 Suppl 3():C15-25. PubMed ID: 21896348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production.
    Ferreira DM; Darrieux M; Oliveira ML; Leite LC; Miyaji EN
    Clin Vaccine Immunol; 2008 Mar; 15(3):499-505. PubMed ID: 18184825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants.
    Dagan R; Kayhty H; Wuorimaa T; Yaich M; Bailleux F; Zamir O; Eskola J
    Pediatr Infect Dis J; 2004 Feb; 23(2):91-8. PubMed ID: 14872172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital admission for Pneumococcal pneumonia.
    Musher DM; Phan HM; Watson DA; Baughn RE
    J Infect Dis; 2000 Jul; 182(1):158-67. PubMed ID: 10882593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined protective effects of anti-PhtD and anti-pneumococcal polysaccharides.
    Denoël P; Godfroid F; Hermand P; Verlant V; Poolman J
    Vaccine; 2011 Sep; 29(38):6451-3. PubMed ID: 21315695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells.
    Goulart C; Darrieux M; Rodriguez D; Pimenta FC; Brandileone MC; de Andrade AL; Leite LC
    Vaccine; 2011 Feb; 29(8):1634-42. PubMed ID: 21211592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection induced by pneumococcal surface protein A (PspA) is enhanced by conjugation to a Streptococcus pneumoniae capsular polysaccharide.
    Csordas FC; Perciani CT; Darrieux M; Gonçalves VM; Cabrera-Crespo J; Takagi M; Sbrogio-Almeida ME; Leite LC; Tanizaki MM
    Vaccine; 2008 Jun; 26(23):2925-9. PubMed ID: 18440673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.